Health Canada approves Brukinsa to treat Waldenstrom’s Macroglobulinemia – BeiGene

BeiGene, Ltd. a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, announced that Brukinsa (zanubrutinib) has been approved by Health Canada for the treatment of adult patients with Waldenström’s Macroglobulinemia (WM).

Waldenstrom’s Macroglobulinemia (WM) is a rare disease with significant morbidity. BTK inhibitors have brought advancements in the treatment of WM, yet not all patients respond and intolerability due to side effects remains an issue, particularly for the elderly patient population,” said Christine Chen, M.D., Med, FRCPC, Associate Professor at University of Toronto and Clinical Investigator at Princess Margaret Cancer Centre. “The ASPEN trial results underscore the potential that zanubrutinib has to provide clinical benefit with advantages in safety, offering new hope for WM patients.”